Literature DB >> 12940804

Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial.

Vincenzo Di Monda1, Maria Nicolodi, Antonina Aloisio, Pierluigi Del Bianco, Marco Fonzari, Irene Grazioli, Carla Uslenghi, Leonardo Vecchiet, Federigo Sicuteri.   

Abstract

OBJECTIVE: To compare the efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine suppositories with sumatriptan suppositories in the treatment of 2 consecutive migraine attacks of moderate or severe intensity in a multicenter, randomized, crossover study.
BACKGROUND: A fixed combination of indomethacin, prochlorperazine, and caffeine is the most commonly used drug for the acute treatment of migraine in Italy. No studies have been published comparing the efficacy of this combination with sumatriptan, the most widely prescribed of the triptans.
METHODS: One hundred twelve patients with migraine with or without aura according to the diagnostic criteria of the International Headache Society were randomized to treat 2 migraine attacks with a fixed combination of indomethacin, prochlorperazine, and caffeine and 2 migraine attacks with sumatriptan. Both drugs were rectally administered in a single dose for each attack. Patients were asked to take study medication as soon as possible at the onset of a headache.
RESULTS: Of the 112 patients, 88 were compliant to the protocol. More attacks became pain-free at 2 hours postdose (primary end point) on the combination than on sumatriptan (49% versus 34%; P<.01), while there was no difference in the relief of headache at 2 hours postdose (71% versus 65%). The combination was statistically superior to sumatriptan in the time to a pain-free response (a higher percentage of attacks became pain-free from 0.5 hours postdose to 5 hours postdose), in alleviation of nausea, and in a sustained pain-free response (pain-free at 2 hours postdose with no use of rescue medication or relapses within 48 hours). Moreover, a significant consistent response was achieved for the combination compared with sumatriptan across (higher percentage of patients pain-free at 2 hours postdose in the first, second, third, and fourth treated attack) and within patients (pain-free in 2 of 2 treated attacks in 35% of patients taking the combination and 20% of patients on sumatriptan). Both drugs were well-tolerated.
CONCLUSIONS: This study, analyzed according to the more recent guidelines for controlled trials in migraine, showed that a fixed combination of indomethacin, prochlorperazine, and caffeine is significantly more effective than sumatriptan in the acute treatment of migraine attacks. It is notable that the combination is less expensive than sumatriptan per unit dose.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940804     DOI: 10.1046/j.1526-4610.2003.03161.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  10 in total

Review 1.  Indomethacin/prochlorperazine/caffeine: a review of its use in the acute treatment of migraine and in the treatment of episodic tension-type headache.

Authors:  Sheridan M Hoy; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 2.  Fixed drug combinations for the acute treatment of migraine : place in therapy.

Authors:  Elizabeth Loder
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.

Authors:  Carla Ghelardini; Nicoletta Galeotti; Elisa Vivoli; Irene Grazioli; Carla Uslenghi
Journal:  J Headache Pain       Date:  2009-09-15       Impact factor: 7.277

Review 4.  Are the current IHS guidelines for migraine drug trials being followed?

Authors:  Anders Hougaard; Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2010-10-08       Impact factor: 7.277

Review 5.  New drugs for migraine.

Authors:  Lars Jacob Stovner; Erling Tronvik; Knut Hagen
Journal:  J Headache Pain       Date:  2009-10-01       Impact factor: 7.277

Review 6.  Sumatriptan (rectal route of administration) for acute migraine attacks in adults.

Authors:  Christopher J Derry; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

7.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

8.  Current migraine management - patient acceptability and future approaches.

Authors:  Arnaud Fumal; Jean Schoenen
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

9.  Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study.

Authors:  G Sandrini; R Cerbo; E Del Bene; A Ferrari; S Genco; I Grazioli; P Martelletti; G Nappi; L Pinessi; P Sarchielli; P Tamburro; C Uslenghi; G Zanchin
Journal:  Int J Clin Pract       Date:  2007-08       Impact factor: 2.503

Review 10.  NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data.

Authors:  Arpad Pardutz; Jean Schoenen
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.